President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
President Donald Trump today signed an executive order on healthcare. The order will allow businesses to form associations that will have the ability to purchase health coverage from across state lines.
Trump said that the ability to purchase such plans would be “Very, very powerful for our nation and very good for a lot of people.” The order also includes provisions for the creation of health plans that will provide short-term, limited-duration coverage, and for exploration of how employers might use health reimbursement arrangements, which are plans that reimburse employees for medical expense paid for out of pocket.
Senator Rand Paul (R-Kentucky) said that “what I believe is the biggest free market reform of healthcare in a generation” that would “…allow millions of people to get insurance across state lines and at an inexpensive price.” Vice President Mike Pence also praised the executive order, saying that it was a “Critical step to lower the cost of health insurance for working Americans.”
While today’s executive order may not be the full repeal of the Affordable Care Act (ACA) that Republicans have promised their supporters, Trump made it clear that today’s effort was part of a larger push to overhaul healthcare: “I just keep hearing repeal, replace; repeal, replace. Well, we’re starting that process,” he said. “I believe we have the votes to do block grants” at a later time, he went on, apparently referring to a plan similar to the one proposed in the Graham-Cassidy healthcare reform bill that recently failed to garner enough support to move to a Senate vote.
Trump also suggested that the ACA individual market would continue to lose participation from insurers, predicting that half of all counties in the nation would have only 1 insurer participating in the ACA health insurance exchanges, and that others would have none. Allowing associations to purchase insurance plans across states would mean that “they will have so many options,” and that competition among plans would be “staggering.”
The president also indicated that the coming months would see his administration taking further measures related to healthcare and to the economy at large. These measures, he promised, would include “massive” tax cuts.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.